Opus Genetics, Inc.

DB:R3X1 Stock Report

Market Cap: €33.1m

Opus Genetics Future Growth

Future criteria checks 2/6

Opus Genetics is forecast to grow earnings and revenue by 64.9% and 62% per annum respectively while EPS is expected to grow by 75.1% per annum.

Key information

64.9%

Earnings growth rate

75.1%

EPS growth rate

Pharmaceuticals earnings growth21.6%
Revenue growth rate62.0%
Future return on equityn/a
Analyst coverage

Low

Last updated13 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:R3X1 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202636-16-2974
12/31/202520-26-38-84
12/31/202418-21-3213
9/30/20248-27-14-14N/A
6/30/202416-14-11-11N/A
3/31/202419-11-3-3N/A
12/31/202319-10-1-1N/A
9/30/202357292323N/A
6/30/202345192222N/A
3/31/202342191717N/A
12/31/202240181414N/A
9/30/2022N/A-22-20-20N/A
6/30/20220-22-19-19N/A
3/31/20221-24-20-20N/A
12/31/20211-57-19-19N/A
9/30/20211-69-20-18N/A
6/30/20210-66-17-16N/A
3/31/2021N/A-61-13-12N/A
12/31/2020N/A-25-8-7N/A
9/30/2020N/A-8-4-4N/A
6/30/2020N/A-9-4-4N/A
3/31/2020N/A-8-4-4N/A
12/31/2019N/A-6-4-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: R3X1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: R3X1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: R3X1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: R3X1's revenue (62% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: R3X1's revenue (62% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if R3X1's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y